Retatrutide 28.7% and Ribupatide 23.6%: The Triple-Agonist Obesity Race Heading Into 2027

Obesity drug design has been moving in one direction for the past ten years: hit more receptors, get more weight loss. Semaglutide (Wegovy, Ozempic) hits one receptor and produces roughly 15 percent mean weight loss. Tirzepatide (Zepbound, Mounjaro) hits two receptors and produces roughly 21 to 25 percent. Two new drugs now hit three receptors at once. Eli Lilly's retatrutide has reached 28.7 percent weight loss in a Phase 3 trial, the highest number ever published for an obesity drug. Kailera Therapeutics and Hengrui Pharma's ribupatide is running behind but has produced 23.6 percent weight loss in a Phase 2 injection trial and up to 12.1 percent in an oral Phase 2 trial.

Both drugs bind and activate the same three receptors: GLP-1, GIP, and glucagon. Each receptor unlocks a different part of the body's metabolic response. Combining all three produces more weight loss than combining any two of them. The question ahead of 2027 is whether the ceiling can go higher still, and whether the ceiling is limited by the receptor coverage or by something else entirely (lean muscle preservation, cardiovascular tolerability, patient adherence over years of therapy).

This piece walks through what a triple agonist is, what each receptor contributes, where retatrutide and ribupatide stand in the clinical timeline, how the delivery formats differ, and what to watch for through the end of 2027.

A receptor is a docking site on the outside of a cell that responds to a specific signal. When the right molecule binds a receptor, the cell changes what it is doing (releasing insulin, slowing digestion, burning stored fat, reducing appetite). An agonist is a molecule that binds a receptor and turns it on. A triple agonist is one molecule that turns on three different receptors at once.

The three receptors involved in retatrutide and ribupatide are all gut hormone receptors: GLP-1, GIP, and glucagon. Each has been studied for decades individually. Combining them into one molecule is recent.

GLP-1 (glucagon-like peptide-1) receptor. Found mainly in the hypothalamus (an appetite control center in the brain) and the gastrointestinal tract. Activating it reduces appetite, slows stomach emptying, and improves the pancreas's insulin response after meals. This is the receptor semaglutide targets.

GIP (glucose-dependent insulinotropic polypeptide) receptor. Found in the hindbrain, the hypothalamus, adipose tissue (fat cells), and bone. Activating it contributes to appetite reduction through slightly different brain pathways than GLP-1, and it has direct effects on fat cells that GLP-1 does not have. GIP appears to partially blunt the nausea that GLP-1 activation causes, letting patients tolerate higher effective doses. This is the second receptor tirzepatide targets.

Glucagon receptor. Found mainly in the liver, but also in brown adipose tissue and other metabolic organs. Activating it tells the liver to break down stored fat and increases energy expenditure (thermogenesis). This is where obesity drug design gets interesting. Glucagon activation, in isolation, would raise blood sugar (which is bad). But when combined with GLP-1 activation, the GLP-1 side controls blood sugar while the glucagon side burns fat. The two effects offset each other on glucose while adding on weight loss. This is the third receptor that retatrutide and ribupatide add.

So the mechanistic story on triple agonists is: appetite control (GLP-1 plus GIP) + fat burning (glucagon) + tolerability (GIP softens the GLP-1 side effects) = more total weight loss with acceptable tolerability.

Retatrutide is once-weekly injectable and is the further-along triple agonist. Eli Lilly has been running a Phase 3 program called TRIUMPH across multiple indications. Seven readouts are expected across 2026, and Lilly is expected to file the drug with the FDA in late 2026 or 2027.

What has read out already:

• TRIUMPH-1 (obesity in adults without type 2 diabetes) met its primary endpoint with 28.7 percent mean weight loss at 68 weeks at the 12 mg weekly dose. This is the highest weight-loss number ever published in a Phase 3 obesity trial.
• TRIUMPH-4 (obesity plus knee osteoarthritis) delivered the same 28.7 percent weight loss and reduced WOMAC pain scores by 75.8 percent. More than one in eight patients on retatrutide finished the trial completely pain-free from their knee osteoarthritis. This is a striking result because knee osteoarthritis in obese adults usually leads to joint replacement surgery. A drug that removes the underlying weight and the pain both would substantially change how orthopedic care is delivered.

What is still to come: type 2 diabetes readouts, obstructive sleep apnea, chronic lower back pain, and cardio-renal-metabolic outcome trials across 2026 and into 2027. If the full package holds up, FDA approval is expected in 2027 or 2028.

The number to watch: 28.7 percent is the current published ceiling. Retatrutide's clinical program has been consistent enough that the ceiling is likely durable rather than a lucky outlier. That would mean the drug launches, if approved, as the most effective pharmacologic obesity treatment ever brought to market.

Ribupatide is the second triple agonist making substantial progress, and its story has a wrinkle worth understanding. The drug was originally developed by Hengrui Pharma, a large Chinese pharmaceutical company. Hengrui licensed the ex-China rights (US, Europe, and other markets) to Kailera Therapeutics (NASDAQ: KLRA), a US-based obesity-focused biotech that went public in 2025. Hengrui keeps the China rights and runs the trials there. Kailera runs the trials for the US and rest of the world.

This licensing structure is common in obesity drug development because Chinese biotech companies have moved fast on GLP-1 and related peptides while the US and European approval process typically requires trials in local patient populations. The Kailera / Hengrui split means the two companies share drug data but move on separate regulatory tracks.

Where the drug stands clinically:

Injection Phase 2. Ribupatide injection has produced 23.6 percent mean weight loss at 8 mg over 36 weeks. This is substantially below retatrutide's 28.7 percent at 68 weeks, though the comparison is not clean (different doses, different durations, different patient populations, different trial designs).

Oral Phase 2. Hengrui's Phase 2 trial of oral ribupatide (25 mg and 50 mg once daily) reached up to 12.1 percent mean weight loss at Week 26 with no observed plateau. Roughly 38.6 percent of participants achieved at least 15 percent weight loss. This is a lower magnitude than the injectable form but delivered in a pill, which changes the market entirely.

Phase 3 plan. Kailera has an active IND with the FDA for oral ribupatide and plans to initiate global Phase 3 obesity trials in the first half of 2027. Data from the fully-enrolled Phase 2b high-dose injection trial in obesity is expected in mid-2027.

Analyst reception has been positive. Six analysts covering KLRA average a Strong Buy rating with a $42.60 twelve-month price target (roughly 82 percent above the recent $18 trading range). TD Cowen has a Buy at $57, and Evercore ISI and William Blair both have Outperform ratings.

The strongest way to see the value of adding glucagon is to compare where each drug class sits on the weight-loss ladder.

• GLP-1 alone (semaglutide): roughly 15 percent at 68 weeks
• Amylin plus GLP-1 (CagriSema): roughly 20 to 23 percent at 68 to 84 weeks
• GIP plus GLP-1 (tirzepatide): roughly 21 to 25 percent at 68 to 84 weeks
• Glucagon plus GIP plus GLP-1 (retatrutide): 28.7 percent at 68 weeks

Each step up the ladder adds another receptor system and roughly 3 to 5 percentage points of weight loss. The pattern suggests that each additional receptor reaches tissues the previous combinations did not. Amylin adds brainstem satiety on top of GLP-1's hypothalamic action but does not reach adipose tissue directly. GIP adds direct adipose tissue effects plus a second central appetite pathway. Glucagon adds hepatic fat burning and thermogenesis on top of everything else.

Of the four receptors that appear in current obesity drugs, glucagon is the one that produces heat and burns stored fat rather than reducing food intake. That is why it adds efficacy in a different way. GLP-1, GIP, and amylin all work primarily through the brain and gut to reduce eating. Glucagon works through the liver and brown fat to increase energy expenditure. Combining eating-reduction pathways with an energy-expenditure pathway is what appears to push retatrutide to the top of the ladder.

The practical implication: any obesity drug that stays only on the appetite-reduction side of biology is likely to top out around 25 percent weight loss. To break past that ceiling, a drug needs to add something that increases energy out on top of reducing energy in. Glucagon is the mechanism that does that in retatrutide and ribupatide. Other approaches under investigation (thyroid receptor beta agonists, uncoupling protein activators) are exploring the same energy-out side of the balance from different angles.

The retatrutide-vs-ribupatide comparison also involves a delivery format split that reshapes the commercial picture.

Retatrutide is injectable only. Once-weekly subcutaneous injection is the standard format for the GLP-1 class, and most patients accept it, but injection is a real barrier for some. Some patients cannot tolerate needles. Some travel frequently and find refrigerated pen storage inconvenient. Some prefer daily pills to weekly shots for adherence reasons. And the manufacturing supply chain for injectables is capital-intensive and slower to scale than pill production.

Kailera and Hengrui are running ribupatide in both formats. The injection targets patients where injectable dosing is acceptable and where the higher weight loss (23.6 percent at 8 mg) matters. The oral targets patients where the lower weight loss (12.1 percent at 25 to 50 mg) is worth accepting to avoid injection.

The oral market matters more than the raw weight-loss numbers suggest. Eli Lilly's oral orforglipron (Foundayo) has already reached $98 million in its first full commercial quarter (Q2 2026) after FDA approval in April 2026, producing 7.5 to 11.2 percent weight loss over 72 weeks. Novo Nordisk's Wegovy pill (oral semaglutide 25 and 50 mg) has reached more than 5 million cumulative US prescriptions since Q1 2026 launch. Oral formulations expand the addressable patient population substantially, even when the efficacy is lower than the injectable version of the same class.

If ribupatide oral holds up in Phase 3 with roughly 12 to 15 percent weight loss and a decent tolerability profile, it becomes a real competitor to Wegovy pill and orforglipron in the oral segment, while retatrutide competes with tirzepatide and CagriSema in the injectable segment. Two different market slices, two different economic pictures.

The manufacturing point is also worth naming. Peptide APIs (active pharmaceutical ingredients) are made through solid-phase peptide synthesis, which is complex, capital-intensive, and currently supply-constrained. Small-molecule pills are far cheaper to manufacture at scale. Ribupatide is a peptide in both formats (the oral is a peptide with an absorption enhancer, similar to Wegovy pill), which means both compete for the same peptide supply chain. Orforglipron is different — it is a non-peptide small molecule targeting the GLP-1 receptor. That gives Lilly the ability to produce orforglipron at pill-manufacturing prices, which is a structural advantage in the oral segment.

The successive weight-loss ceiling that each new drug class sets has extended by 3 to 5 percentage points at a time. The question ahead is how far it can keep extending.

Several factors suggest a real ceiling exists somewhere in the 30 to 35 percent range, though nobody knows exactly where.

Lean mass preservation. All obesity drugs cause some loss of muscle along with fat. Semaglutide loses roughly 25 percent lean mass in the total weight lost. Tirzepatide is similar. Retatrutide's lean-mass numbers are not fully public yet. Aggressive weight loss without preserved muscle is a functional problem: patients get weaker, have less balance, and are at higher risk of falls in the years after therapy. Somewhere in the ceiling range, the drug is producing weight loss faster than muscle can be preserved even with resistance training and adequate protein.

Cardiovascular tolerability. Rapid weight loss stresses the cardiovascular system. Most patients tolerate it, but subgroups (older adults, patients with pre-existing heart disease) are at higher risk during rapid loss. Retatrutide's cardio-renal-metabolic Phase 3 outcomes trials will test this.

Patient adherence. All of these drugs are chronic therapies. Real-world data on semaglutide and tirzepatide shows adherence drops steadily over the first year and continues declining after that. Gastrointestinal side effects, cost, and the return of hunger after stopping all contribute. A drug that produces 35 percent weight loss but that patients cannot stay on for more than 18 months will not deliver 35 percent long-term.

Cost and access. Higher-efficacy drugs are almost always priced above lower-efficacy predecessors. If retatrutide launches at Wegovy or Zepbound price points, insurance coverage will be limited to the highest-BMI patients and those with substantial obesity-related comorbidities. Real-world weight loss in the population is a function of who can afford the drug, beyond what the drug can do at maximum efficacy.

What this means for the triple-agonist race: retatrutide's 28.7 percent is likely near the pharmacologic ceiling for the appetite-plus-energy-expenditure approach. Ribupatide, if it holds up in Phase 3, may top out around 25 percent (roughly where tirzepatide is). Future drugs pushing past 30 percent will probably need to add a substantially different mechanism (uncoupling proteins, thyroid receptor beta, or something else) rather than simply adding a fourth incretin receptor. Or they will need to focus on the delivery-format and adherence side of the equation rather than the raw efficacy side.

For patients considering the obesity drug landscape over the next 18 months, the practical picture looks like this:

Retatrutide is likely two years away from routine prescribing. Even if Lilly files in late 2026 or 2027, FDA review typically takes 10 months for standard review or 6 months for priority review, and formulary access at insurance plans takes another 6 to 12 months after approval. A patient considering obesity drug therapy in 2026 or early 2027 is choosing from what is already approved (semaglutide, tirzepatide, orforglipron, upcoming higher-dose Wegovy 7.2 mg, likely CagriSema by late 2026 or early 2027). Retatrutide is not on the near-term menu.

Ribupatide is at least three years away. Global Phase 3 starts in H1 2027; enrollment and follow-up runs 15 to 24 months; FDA review is 10 months; formulary access is another 6 to 12 months. Realistic ribupatide availability is 2029 or later. For anyone comparing shopping-list options, ribupatide is a story about the future, not the present.

Currently approved options still deliver substantial weight loss. For most patients, tirzepatide's 21 to 25 percent or semaglutide's 15 percent is substantial weight loss. The gap to retatrutide's 28.7 percent is real but not so large that waiting two extra years makes sense in most clinical situations.

Prescribing decisions belong with a clinician. Individual response varies substantially. Some patients on semaglutide lose more than 30 percent, and some on tirzepatide lose less than 15 percent. Comorbidities, insurance coverage, tolerability, and preference on injection frequency all matter. A prescriber can weigh those together in a way that a class comparison cannot.

Several concrete milestones will shape the triple-agonist race over the next 18 months.

Additional retatrutide TRIUMPH readouts across 2026 in type 2 diabetes (TRIUMPH-2), obstructive sleep apnea, chronic lower back pain, and cardio-renal-metabolic outcomes. Consistent efficacy across indications strengthens the FDA submission package. Adverse safety signals in any of them (particularly cardiovascular events during rapid weight loss) would complicate the label.

FDA filing decision on retatrutide in late 2026 or 2027. Priority Review Voucher redemption would shorten the review from 10 months to 6 months (see the recent Arrowhead $215 million PRV insight for how that math works). Lilly has not signaled whether it plans to use a PRV, but the strategic value of accelerating an obesity blockbuster launch by four months could easily justify the current $200 to $250 million market rate for a voucher.

Ribupatide injection Phase 2b data expected mid-2027. This is the higher-dose trial that will inform whether ribupatide injection can push into the 26 to 28 percent range that would make it competitive with retatrutide, or whether it tops out closer to tirzepatide territory at 21 to 25 percent.

Ribupatide global Phase 3 initiation in H1 2027. Trial design (comparator arm, duration, patient population) will shape how the injectable and oral formulations compete with the approved GLP-1 landscape.

Novo Nordisk's response. Novo Nordisk shares fell approximately 6 percent Thursday August 13 on the ongoing CagriSema head-to-head miss against tirzepatide and franchise-gap pressure from Lilly. The next-generation candidates Novo is running (amycretin oral amylin monotherapy at Phase 3 with roughly 22 percent weight loss in Phase 1b, higher-dose CagriSema Phase 3 planned for H2 2026) will need to hold the line while the triple agonists advance.

Other next-generation candidates. Amgen's MariTide (monthly dual GLP-1 antagonist / GIP agonist) has 6 Phase 3 trials running. Viking Therapeutics' VK2735 (dual GLP-1/GIP agonist, similar to tirzepatide) is fully enrolled in Phase 3 VANQUISH with 2027 readouts. Viking also announced VK3019, a dual amylin plus calcitonin receptor agonist, entering Phase 1. Boehringer / Zealand's survodutide (GLP-1 plus glucagon dual agonist without GIP) is in ongoing Phase 3. Each of these tests a slightly different receptor combination and delivery format.

The race extends beyond retatrutide and ribupatide. It is a broader test of whether the ceiling extends further, whether oral formulations can catch up on efficacy, and whether delivery-format innovation (monthly injectables, once-daily orals, longer-acting depots) can differentiate drugs that end up in the same efficacy tier.

The triple-agonist race is a specific chapter in the broader arc of obesity drug development that started with semaglutide's 15 percent and has moved through tirzepatide's 25.5 percent to retatrutide's 28.7 percent. Adding the glucagon receptor to the GLP-1 plus GIP combination pushes the ceiling by roughly 3 percentage points and adds mechanistic breadth (energy expenditure through the liver and brown fat, on top of appetite reduction through the brain and gut).

Retatrutide is ahead by roughly two years. Its 28.7 percent weight loss result at 68 weeks in TRIUMPH-1 and TRIUMPH-4 is the highest number ever published in a Phase 3 obesity trial. Filing is expected late 2026 or 2027 and approval in 2027 or 2028.

Ribupatide is behind but coming with an oral formulation, which changes the market picture. Global Phase 3 starts in H1 2027 for the oral and mid-2027 readouts on the injection Phase 2b. Availability is 2029 or later.

The ceiling on pharmacologic weight loss looks like it is somewhere in the 30 to 35 percent range, limited by muscle preservation, cardiovascular tolerability, and long-term adherence rather than by receptor combinations alone. Retatrutide is likely close to that ceiling. Future gains will come from delivery-format differentiation, adherence improvements, and mechanistically different approaches (energy expenditure through non-glucagon pathways) rather than from adding a fourth incretin receptor.

For patients, the retatrutide-ribupatide race is a story about 2027 through 2029, not about today. Currently approved drugs still deliver substantial weight loss, and prescribing decisions are worth making with a clinician on the basis of individual response and tolerability rather than waiting for a marginally better next-generation option.